192 Article(s)Download |
||||||
PMID | Title | Pub. Year | #Total Relationships |
|||
1 | 34741720 | Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers. | 2022 Feb | 2 | ||
2 | 35199646 | Acromegaly caused by a GHRH-producing pancreatic neuroendocrine tumor: a rare manifestation of MEN1 syndrome. | 2022 Feb 1 | 1 | ||
3 | 34599040 | Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone-Inhibitory Effect of Octreotide after Growth Hormone-Releasing Hormone Stimulation. | 2021 Dec | 5 | ||
4 | 32859050 | Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. | 2020 Aug 26 | 1 | ||
5 | 29699852 | Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects. | 2018 May | 1 | ||
6 | 28260048 | Octreotide inhibits the proliferation of gastric cancer cells through P300-HAT activity and the interaction of ZAC and P300. | 2017 Apr | 2 | ||
7 | 26610414 | New therapeutic agents for acromegaly. | 2016 Feb | 1 | ||
8 | 26951062 | Somatostatin and its Analogs. | 2016 | 1 | ||
9 | 27376425 | Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center. | 2016 Apr | 1 | ||
10 | 27657985 | Comparative pharmacokinetic and pharmacodynamic evaluation between a new biosimilar and reference recombinant human growth hormone. | 2016 Oct - Dec | 1 | ||
11 | 25345412 | Evaluation of the antiangiogenic effects of octreotide on growth hormone-producing pituitary adenoma using arterial spin-labeling perfusion imaging. | 2015 | 2 | ||
12 | 26115707 | Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. | 2015 Dec | 2 | ||
13 | 26361517 | Glycemic profile in patients with acromegaly treated with somatostatin analogue. | 2015 | 1 | ||
14 | 24166706 | The role of primary pharmacological therapy in acromegaly. | 2014 Jan | 1 | ||
15 | 25132171 | Thyroid storm induced by TSH-secreting pituitary adenoma: a case report. | 2014 | 1 | ||
16 | 25253414 | Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly. | 2014 Oct | 1 | ||
17 | 22539587 | Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. | 2012 Jul | 1 | ||
18 | 22574156 | Meta-analysis on the effects of octreotide on tumor mass in acromegaly. | 2012 | 2 | ||
19 | 22784835 | A subcutaneous octreotide hydrogel implant for the treatment of acromegaly. | 2012 Nov-Dec | 1 | ||
20 | 22990736 | Ectopic growth hormone-secreting pituitary adenoma involving the clivus treated with octreotide: role of magnetic resonance imaging in the diagnosis and clinical follow-up. | 2012 Sep | 1 | ||
21 | 23148190 | The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy. | 2012 Feb | 2 | ||
22 | 21521254 | Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. | 2011 Jun | 3 | ||
23 | 21979989 | Octreotide for the treatment of systemic lupus erythematosus: clinical effects and an in vitro study on its therapeutic mechanism. | 2011 Oct | 2 | ||
24 | 19884028 | Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR. | 2010 Apr | 1 | ||
25 | 20067380 | Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge. | 2010 Jan | 1 | ||
26 | 20464704 | Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? | 2010 Mar-Apr | 5 | ||
27 | 20723227 | Symptomatic cerebral oedema during treatment of diabetic ketoacidosis: effect of adjuvant octreotide infusion. | 2010 Aug 19 | 2 | ||
28 | 22791498 | Normalisation of plasma growth hormone levels improved cardiac dysfunction due to acromegalic cardiomyopathy with severe fibrosis. | 2010 Sep 19 | 2 | ||
29 | 19164866 | Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas. | 2009 | 6 | ||
30 | 19420816 | Improvement of congestive heart failure after octreotide and transsphenoidal surgery in a patient with acromegaly. | 2009 | 1 | ||
31 | 19625744 | Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. | 2009 | 1 | ||
32 | 19697885 | [Recent trends in the pathophysiology and treatment of pituitary adenomas]. | 2009 Aug | 1 | ||
33 | 18198230 | Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. | 2008 Apr | 1 | ||
34 | 18230656 | Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. | 2008 Apr | 1 | ||
35 | 18348909 | Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. | 2008 Oct | 1 | ||
36 | 18445999 | Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. | 2008 Jul | 2 | ||
37 | 18593770 | Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. | 2008 Sep | 1 | ||
38 | 19074883 | Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. | 2008 Dec 15 | 5 | ||
39 | 17289896 | Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. | 2007 Feb 1 | 3 | ||
40 | 17309144 | Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. | 2007 Feb | 1 | ||
41 | 17642426 | Successful treatment of an invasive growth hormone-secreting pituitary macroadenoma in an 8-year-old boy. | 2007 May | 2 | ||
42 | 20298292 | Yellow nail syndrome: treatment with octreotide. | 2007 Dec | 1 | ||
43 | 16269873 | Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. | 2006 | 1 | ||
44 | 16584524 | Inadequate growth hormone suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' growth hormone levels. | 2006 Apr | 2 | ||
45 | 16817834 | Inadequate growth hormone (GH) suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' GH levels. | 2006 Jul | 3 | ||
46 | 16840917 | An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant. | 2006 Jun | 2 | ||
47 | 17047391 | Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. | 2006 | 2 | ||
48 | 31627642 | [Drug treatment for acromegaly: results of long-term use of Sandostatin LAR]. | 2006 Aug 15 | 4 | ||
49 | 15806331 | Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. | 2005 May | 1 | ||
50 | 15844307 | Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery. | 2005 Mar | 2 |